The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge.
暂无分享,去创建一个
Yen-Ming Hsu | Allan D Kirk | D. Harlan | A. Kirk | C. Benjamin | S. Kalled | Y. Hsu | N. Kenyon | L. Burkly | A. H. Cutler | F. Taylor | E. Garber | David M Harlan | Janine L Ferrant | Christopher D Benjamin | Anne H Cutler | Susan L Kalled | Ellen A Garber | Donna M Hess | Renee I Shapiro | Norma S Kenyon | Linda C Burkly | Frederick R Taylor | D. Hess | J. Ferrant | R. Shapiro
[1] C. Conner. Therapy with Monoclonal Antibodies , 1984, Drug intelligence & clinical pharmacy.
[2] M. Sykes,et al. Mechanisms Involved in the Establishment of Tolerance Through Costimulatory Blockade and BMT: Lack of Requirement for CD40L‐Mediated Signaling for Tolerance or Deletion of Donor‐reactive CD4+ Cells , 2001, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[3] R. Flavell,et al. CD40 and CD154 in cell-mediated immunity. , 1998, Annual review of immunology.
[4] D. Yin,et al. The Immunobiology of Inductive Anti‐CD40L Therapy in Transplantation: Allograft Acceptance is Not Dependent Upon the Deletion of Graft‐Reactive T Cells , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[5] D. Harlan,et al. The role of CD154 in organ transplant rejection and acceptance. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[6] F. Gao,et al. The CD154-CD40 T Cell Costimulation Pathway Is Required for Host Sensitization of CD8+ T Cells by Skin Grafts Via Direct Antigen Presentation1 , 2002, The Journal of Immunology.
[7] B. Kumpel,et al. Functional interactions of aglycosylated monoclonal anti-D with Fc gamma RI+ and Fc gamma RIII+ cells. , 1991, Immunology.
[8] L. Burkly. CD40 pathway blockade as an approach to immunotherapy. , 2001, Advances in experimental medicine and biology.
[9] J. Thompson,et al. 2 A crystal structure of an extracellular fragment of human CD40 ligand. , 1995, Structure.
[10] J Bajorath,et al. Immune regulation by CD40 and its ligand GP39. , 1996, Annual review of immunology.
[11] J. Isaacs,et al. Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential. , 1992, Journal of immunology.
[12] S. Hobbs,et al. Interaction of aglycosyl immunoglobulins with the IgG Fc transport receptor from neonatal rat gut: comparison of deglycosylation by tunicamycin treatment and genetic engineering. , 1992, Molecular immunology.
[13] T. Strom,et al. CD154 on the surface of CD4+CD25+ regulatory t cells contributes to skin transplant tolerance , 2003, Transplantation.
[14] K. Strauch,et al. Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody. , 2001, Structure.
[15] S L Morrison,et al. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. , 1989, Journal of immunology.
[16] S. Gillies,et al. Aglycosylated chimeric mouse/human IgG1 antibody retains some effector function. , 1991, Hybridoma.
[17] E. Simpson,et al. Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade , 2003, Nature Medicine.
[18] G. Kelsoe. Therapeutic CD154 antibody for lupus: promise for the future? , 2003, The Journal of clinical investigation.
[19] T. Strom,et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance , 1999, Nature Medicine.
[20] S. Kalled,et al. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. , 1998, Journal of immunology.
[21] R. Jefferis,et al. Aglycosylated chimaeric human IgG3 can trigger the human phagocyte respiratory burst. , 1993, Molecular immunology.
[22] A. Fischer,et al. Clinical spectrum of X-linked hyper-IgM syndrome. , 1997, The Journal of pediatrics.
[23] S. Lederman,et al. Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help) , 1992, The Journal of experimental medicine.
[24] H. Widner,et al. Simultaneous inhibition of B7 and LFA‐1 signaling prevents rejection of discordant neural xenografts in mice lacking CD40L , 2002, Xenotransplantation.
[25] G. Sármay,et al. A protein structural change in aglycosylated IgG3 correlates with loss of huFc gamma R1 and huFc gamma R111 binding and/or activation. , 1990, Molecular immunology.
[26] T. Strom,et al. Reply to Failure of combined costimulatory blockade in animal transplant model , 2000, Nature Medicine.
[27] P. Libby,et al. Host CD40 Ligand Deficiency Induces Long-Term Allograft Survival and Donor-Specific Tolerance in Mouse Cardiac Transplantation But Does Not Prevent Graft Arteriosclerosis1 , 2000, The Journal of Immunology.
[28] M. Sykes,et al. Mechanisms of transplant tolerance induction using costimulatory blockade. , 2002, Current opinion in immunology.
[29] R. Geha,et al. Contribution of CD40-CD154-mediated costimulation to an alloresponse in vivo. , 1999, Transplantation.
[30] A K Patel,et al. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. , 1995, Molecular immunology.
[31] D R Burton,et al. Effector functions of a monoclonal aglycosylated mouse IgG2a: binding and activation of complement component C1 and interaction with human monocyte Fc receptor. , 1985, Molecular immunology.
[32] D. Harlan,et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates , 1999, Nature Medicine.
[33] T. Yokota,et al. Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant , 2005, Cancer Immunology, Immunotherapy.
[34] R. Furie,et al. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. , 2002, Arthritis and rheumatism.
[35] W. Jusko,et al. Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys. , 1998, The Journal of pharmacology and experimental therapeutics.
[36] T. Strom,et al. The complement dependent cytotoxicity (CDC) immune effector mechanism contributes to anti-CD154 induced immunosuppression. , 2002, Transplantation.
[37] H. Wigzell,et al. Biological significance of carbohydrate chains on monoclonal antibodies. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[38] P. Lipsky,et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. , 2003, The Journal of clinical investigation.
[39] G. Sármay,et al. A protein structural change in aglycosylated IgG3 correlates with loss of huFcγR1 and hufcγR111 binding and/or activation , 1990 .
[40] G. Illei,et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. , 2003, Arthritis and rheumatism.
[41] C. Larsen,et al. Analysis of the CD40 and CD28 pathways on alloimmune responses by CD4+ T cells in vivo. , 2001, Transplantation.
[42] D. Harlan,et al. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. , 1999, Proceedings of the National Academy of Sciences of the United States of America.